EGFR and colorectal carcinoma: Overexpression of epidermal growth factor receptor (EGFR) has been identified in 49–80% of CRC, and RAS mutations have been identified as a predictor of poor response to anti-EGFR mAb treatment in mCRC [15,16,17,18].